Home/ Stocks/ CGTX

Cognition Therapeutics, Inc. Common Stock

CGTX XNAS

$1.21 +0.06 (+5.17%) ▲ 15-min delayed

Open

$1.17

High

$1.23

Low

$1.15

Volume

694.3K

Market Cap

$108.12M

About Cognition Therapeutics, Inc. Common Stock

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 14 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-23,487,000	$-0.32
FY 2025	$0	$-23,487,000	$-0.32
Q3 2025	$0	$-4,930,000	$-0.06
Q2 2025	$0	$-6,734,000	$-0.11

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for CGTX yet. Check out our latest market news or earnings calendar.

Get CGTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Cognition Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.